ly 274614 has been researched along with clebopride in 1 studies
Studies (ly 274614) | Trials (ly 274614) | Recent Studies (post-2010) (ly 274614) | Studies (clebopride) | Trials (clebopride) | Recent Studies (post-2010) (clebopride) |
---|---|---|---|---|---|
96 | 0 | 15 | 116 | 17 | 11 |
Protein | Taxonomy | ly 274614 (IC50) | clebopride (IC50) |
---|---|---|---|
Acetylcholinesterase | Homo sapiens (human) | 0.89 | |
D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.017 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.6026 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Awere, S; Blackman, A; Leander, JD; Moore, NA | 1 |
1 other study(ies) available for ly 274614 and clebopride
Article | Year |
---|---|
NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists.
Topics: Animals; Benzamides; Benzazepines; Catalepsy; Chlordiazepoxide; Dizocilpine Maleate; Dopamine D2 Receptor Antagonists; Haloperidol; Isoquinolines; Male; Rats; Receptors, Dopamine D1; Receptors, N-Methyl-D-Aspartate | 1993 |